Clinical Trial Update: Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA) [Phase 2]

View source ↗

Summary

A Phase 2 trial of rilonacept for Deficiency of interleukin-1 receptor antagonist (DIRA) has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deficiency of Interleukin-1 Receptor Antagonist

Drugs mentioned

• Arcalyst (rilonacept)

Snippet

Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Conditions: DIRA | Phase 2 | Status: COMPLETED | Results posted: 2017-10-16